Trial Profile
A Phase I, Double-Blind, Randomized, Multiple-Dose, Pilot Study Comparing Xanomeline Administered Alone to Xanomeline Administered in Combination With Trospium Chloride in Normal Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Dec 2020
Price :
$35
*
At a glance
- Drugs Trospium chloride (Primary) ; Xanomeline (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Proof of concept
- Sponsors Karuna Pharmaceuticals
- 19 Jun 2018 According to the PureTech media release, Wellcome previously awarded Karuna $3.8 million to fund this trial.
- 19 May 2017 According to a Karuna Pharmaceuticals media release, data from this study will be presented at The American Society of Clinical Psychopharmacology (ASCP) Annual Meeting 2017.
- 19 May 2017 According to a Karuna Pharmaceuticals media release, data from this study will be presented at The Society of Biological Psychiatry's (SOBP) 72nd Annual Scientific Program and Convention 2017.